133 related articles for article (PubMed ID: 12581565)
21. Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
Krug LM; Miller VA
Semin Oncol; 1999 Oct; 26(5 Suppl 16):24-6; discussion 41-2. PubMed ID: 10585005
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Krug LM; Miller VA; Patel J; Crapanzano J; Azzoli CG; Gomez J; Kris MG; Heelan RT; Pizzo B; Tyson L; Sheehan C; Ross JS; Venkatraman E
Cancer; 2005 Nov; 104(10):2149-55. PubMed ID: 16208701
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Shi Y; Chen L; Li J; Lv YL; Sun Q; Wang LX; Jiao SC
Tumour Biol; 2011 Apr; 32(2):381-90. PubMed ID: 21086091
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer.
Miller V
Semin Oncol; 1999 Jun; 26(3 Suppl 10):12-4. PubMed ID: 10437745
[TBL] [Abstract][Full Text] [Related]
25. Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study.
Rodríguez J; Calvo E; Cortes J; Santisteban M; Perez-Calvo J; Martínez-Monge R; Brugarolas A; Fernández-Hidalgo O
Breast Cancer Res Treat; 2002 Nov; 76(1):47-56. PubMed ID: 12408375
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel: a review of its use in non-small cell lung cancer.
Comer AM; Goa KL
Drugs Aging; 2000 Jul; 17(1):53-80. PubMed ID: 10933515
[TBL] [Abstract][Full Text] [Related]
28. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Kourousis C; Androulakis N; Kakolyris S; Souglakos J; Maltezakis G; Metaxaris G; Chalkiadakis G; Samonis G; Vlachonikolis J; Georgoulias V
Cancer; 1998 Nov; 83(10):2083-90. PubMed ID: 9827712
[TBL] [Abstract][Full Text] [Related]
29. Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer.
Georgoulias VA
Lung Cancer; 2002 Dec; 38 Suppl 3():S61-6. PubMed ID: 12468149
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel in the management of advanced non-small cell lung cancer.
Miller VA
Semin Oncol; 1998 Jun; 25(3 Suppl 8):15-9. PubMed ID: 9704671
[TBL] [Abstract][Full Text] [Related]
31. A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.
Govindan R; Lim WT; Arquette MA; Goodner SA; Fears CL; Mortimer JE; Fracasso PM
Oncol Rep; 2006 Jan; 15(1):123-7. PubMed ID: 16328044
[TBL] [Abstract][Full Text] [Related]
32. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027).
Hesketh PJ; Chansky K; Lau DH; Doroshow JH; Moinpour CM; Chapman RA; Goodwin JW; Gross HM; Crowley JJ; Gandara DR
J Thorac Oncol; 2006 Jul; 1(6):537-44. PubMed ID: 17409914
[TBL] [Abstract][Full Text] [Related]
33. [A meta-analysis of platinum plus docetaxel or vinorelbine in the first-line treatment of advanced non-small cell lung cancer].
Liu T; Wu H; Zhuang X; Lu D; Cai R; Wang W
Zhongguo Fei Ai Za Zhi; 2014 Apr; 17(4):327-35. PubMed ID: 24758908
[TBL] [Abstract][Full Text] [Related]
34. Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02).
Vázquez S; Huidobro G; Amenedo M; Fírvida JL; León L; Lázaro M; Grande C; Mel JR; Ramos M; Salgado M; Casal J
Anticancer Drugs; 2007 Nov; 18(10):1201-6. PubMed ID: 17893521
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC).
Vergnenègre A; Daniel C; Léna H; Fournel P; Kleisbauer JP; Le Caer H; Letreut J; Paillotin D; Pérol M; Bouchaert E; Preux PM; Robinet G;
Lung Cancer; 2005 Mar; 47(3):395-404. PubMed ID: 15713523
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.
Karampeazis A; Vamvakas L; Agelidou A; Kentepozidis N; Chainis K; Chandrinos V; Vardakis N; Pallis AG; Christophyllakis C; Georgoulias V
Clin Lung Cancer; 2011 May; 12(3):155-60. PubMed ID: 21663857
[TBL] [Abstract][Full Text] [Related]
37. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
Gebbia V; Galetta D; Riccardi F; Gridelli C; Durini E; Borsellino N; Gebbia N; Valdesi M; Caruso M; Valenza R; Pezzella G; Colucci G;
Lung Cancer; 2002 Aug; 37(2):179-87. PubMed ID: 12140141
[TBL] [Abstract][Full Text] [Related]
38. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
Yaren A; Oztop I; Kargi A; Ulukus C; Onen A; Sanli A; Binicier O; Yilmaz U; Alakavuklar M
Int J Clin Pract; 2006 Jun; 60(6):675-82. PubMed ID: 16805752
[TBL] [Abstract][Full Text] [Related]
39. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
Khuri FR
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
